MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Clinical trials for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD) explained in plain language.
Never miss a new study
Get alerted when new MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD) trials appear
Sign up with your email to follow new studies for MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trial aims to tame rare neurological disease Flare-Ups
Disease control Recruiting nowThis study is testing whether the drug satralizumab can prevent relapses in people with MOG antibody-associated disease (MOGAD), a rare condition that causes inflammation in the brain and spinal cord. The trial will enroll 152 participants aged 12 and older who have had recent di…
Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Scientists scan 700 brains to unlock secrets of aging and disease
Knowledge-focused Recruiting nowThis study aims to understand how the brain changes in various neurological diseases and during healthy aging. Researchers will use advanced MRI scans on 700 participants, including people with conditions like Multiple Sclerosis and Alzheimer's, as well as healthy volunteers. The…
Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Knowledge-focused
Last updated Apr 04, 2026 03:51 UTC